We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · June 07, 2021

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy

Circulation

 

Additional Info

Disclosure statements are available on the authors' profiles:

Circulation
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol
Circulation 2021 May 16;[EPub Ahead of Print], SL Heck, A Mecinaj, AH Ree, P Hoffmann, JE Schulz-Menger, MW Fagerland, B Gravdehaug, H Røsjø, K Steine, J Geisler, G Gulati, T Omland

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading